Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Inclusion Criteria:

1. Completed study LA38-0411
2. Females of childbearing potential must have a negative pregnancy test result at Visit
3. In addition, if applicable, they must:

• Use an effective method of contraception according to local requirements, duringthe study and within 30 days following their last dose of study medication, OR
• Have had a tubal ligation (supporting evidence required), OR
• Have had a hysterectomy (supporting evidence required), OR
• Participate in a non-heterosexual lifestyle, OR
• Have a male sexual partner who has been sterilized (supporting evidence required)

3. Fertile heterosexual males and/or their partners must agree to use an effective methodof contraception during the study and for 30 days following the last dose of studymedication
4. All patients and/or their authorized legal representatives must provide signed anddated written informed consent prior to the first study intervention, and assent willbe obtained from patients who are considered to be minors. Patients must be able toadhere to study restrictions, appointments, and evaluation schedules.

Exclusion Criteria:

1. Plan to participate in another clinical trial at any time from the day of enrollmentuntil 30 days post-treatment in the current study
2. For only those patients who were treated with deferoxamine in study LA38-0411 (Group 2): Presence of any medical condition (including clinically significant laboratoryabnormalities, such as ALT (alanine aminotransferase) ≥ 5 x ULN or creatinine ≥ 2 xULN), psychological condition, or psychiatric condition which in the opinion of theinvestigator would cause participation in the study to be unwise.
3. Pregnant, breastfeeding, or planning to become pregnant during the study period.
4. Treatment failure after 1 year on deferiprone which in the investigator's judgmentindicates the need for the patient to be started on a different iron chelator